KB-1256

Telisotuzumab

Background

c-Met is a transmembrane receptor tyrosine kinase that is encoded by the MET proto-oncogene and activated upon binding to the hepatocyte growth factor. Dysregulation of c-Met is observed in several types of cancer, including overexpression in approximately 50% of NSCLC. Telisotuzumab vedotin (ABBV-399; Teliso-V) is a first-in-class antibody-drug conjugate (ADC) that uses a cleavable linker to combine a recombinant c-Met–targeting humanized monoclonal antibody (ABT-700) and monomethyl auristatin E (MMAE), a potent inhibitor of microtubule polymerization.

Specifications

Catalog Number:
KB-1256
Cell Line Name:
Telisotuzumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
MET
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Ma PC, Tretiakova MS, MacKinnon AC, et al.: Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47:1025-1037, 2008. 2. Heist RS, Motwani M, Barlesi F, et al.: c-Met expression and response to telisotuzumab vedotin (Teliso-v) in patients with non-small cell lung cancer. J Clin Oncol 37:9023-90123, 2019. 3. Camidge DR, Goldman JW, Cole GW, et al.: Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort. Ann Oncol 31:S894, 2020.
Please enable JavaScript in your browser to complete this form.